Clinical Trial Update: Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and pharmacokinetics of DMUC5754A administered intravenously in patients with platinum-resistant ovarian cancer or unresecta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• DMUC5754A (DMUC5754A)

Snippet

Sponsor: Genentech, Inc. | Conditions: Ovarian Cancer, Pancreatic Cancer | Phase 1 | Status: COMPLETED